Search


Current filters:


Start a new search
Add filters:

Use filters to refine the search results.


Results 1-10 of 38 (Search time: 0.01 seconds).
Item hits:
PreviewIssue DateTitleAuthor(s)
2014Long-term response to imatinib is not affected by the initial dose in patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: final update from the Tyrosine Kinase Inhibitor Optimization and Selectivity (TOPS) studyBaccarani, M.; Druker, B.; Branford, S.; Kim, D.; Pane, F.; Mongay, L.; Mone, M.; Ortmann, C.; Kantarjian, H.; Radich, J.; Hughes, T.; Cortes, J.; Guilhot, F.
2017Long-term outcomes of imatinib treatment for chronic myeloid leukemiaHochhaus, A.; Larson, R.; Guilhot, F.; Radich, J.; Branford, S.; Hughes, T.; Baccarani, M.; Deininger, M.; Cervantes, F.; Fujihara, S.; Ortmann, C.; Menssen, H.; Kantarjian, H.; O'Brien, S.; Druker, B.
2010Establishment of the first World Health Organization International Genetic Reference Panel for quantitation of BCR-ABL mRNABranford, S.; Hughes, T.
2019Lenalidomide maintenance treatment after imatinib discontinuation: results of a phase 1 clinical trial in chronic myeloid leukaemiaRoss, D.; Pagani, I.; Irani, Y.; Clarson, J.; Leclercq, T.; Dang, P.; McLean, J.; Saunders, V.; Carne, L.; Reynolds, J.; Ritchie, D.; White, D.; Branford, S.; Hughes, T.; Yong, A.
2014Deep molecular responses achieved in patients with CML-CP who are switched to nilotinib after long-term imatinibHughes, T.; Lipton, J.; Spector, N.; Cervantes, F.; Pasquini, R.; Clementino, N.; Dorlhiac Llacer, P.; Schwarer, A.; Mahon, F.; Rea, D.; Branford, S.; Purkayastha, D.; Collins, L.; Szczudlo, T.; Leber, B.
2010Phase III, randomized, open-label study of daily Imatinib Mesylate 400 mg versus 800 mg in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase using molecular end points: Tyrosine Kinase Inhibitor Optimization and Selectivity StudyCortes, A.; Baccarani, M.; Guilhot, F.; Druker, B.; Branford, S.; Kim, D.; Pane, F.; Pasquini, R.; Goldberg, S.; Kalaycio, M.; Moiraghi, B.; Rowe, J.; Tothova, E.; de Souza, C.; Rudoltz, M.; Yu, R.; Krahnke, T.; Kantarjian, H.; Radich, J.; Hughes, T.
2018Long-term treatment-free remission of chronic myeloid leukemia with falling levels of residual leukemic cellsRoss, D.; Pagani, I.; Shanmuganathan, N.; Kok, C.; Seymour, J.; Mills, A.; Filshie, R.; Arthur, C.; Dang, P.; Saunders, V.; Braley, J.; Yong, A.; Yeung, D.; White, D.; Grigg, A.; Schwarer, A.; Branford, S.; Hughes, T.
2016BCR-ABL1 expression, RT-qPCR and treatment decisions in chronic myeloid leukaemiaLatham, S.; Bartley, P.; Budgen, B.; Ross, D.; Hughes, E.; Branford, S.; White, D.; Hughes, T.; Morley, A.
2010Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS)Hughes, T.; Hochhaus, A.; Branford, S.; Muller, M.; Kaeda, J.; Foroni, L.; Druker, B.; Guilhot, F.; Larson, R.; O'Brien, S.; Rudoltz, M.; Mone, M.; Wehrle, E.; Modur, V.; Goldman, J.; Radich, J.
2010Patients with chronic myeloid leukemia who maintain a complete molecular response after stopping imatinib treatment have evidence of persistent leukemia by DNA PCRRoss, D.; Branford, S.; Seymour, J.; Schwarer, A.; Arthur, C.; Bartley, P.; Slader, C.; Field, C.; Dang, P.; Filshie, R.; Mills, A.; Grigg, A.; Vaz de Melo, J.; Hughes, T.